What Ventyx Biosciences does

Ventyx Biosciences was a clinical-stage biopharmaceutical company founded in 2018 and headquartered in San Diego, California (Delaware-incorporated), focused on developing oral small-molecule therapies for patients with autoimmune and inflammatory disorders. The company's core technology is an NLRP3 inflammasome inhibitor platform targeting the innate immune system, with pipeline assets including VTX3232 (a CNS-penetrant NLRP3 inhibitor for Parkinson's disease and cardiovascular risk reduction that reduced hsCRP by nearly 80% within one week in a 175-patient Phase 2 study), VTX2735 (Phase 2 for recurrent pericarditis), VTX958/tamuzimod (IL-17-related inflammatory bowel disease program), and preclinical VEN-201 for spinal cord injury.

The business model was that of a pre-revenue clinical-stage biotech: revenue mechanics depended on future commercialization, licensing royalties, or partnership/M&A transactions rather than current product sales. The company pursued a sales-led biotech go-to-market via clinical trials and regulatory engagement, distributed clinical supply through trial sites globally (with VTX2732/2735 expansion into Canada, EU, and UK), and communicated progress via investor press releases and healthcare conferences rather than traditional commercial channels. Communication reached shareholders and the investment community through channels such as GlobeNewsWire/PR Newswire and events such as the Piper Sandler Healthcare Conference.

Customer-facing commercialization never began prior to acquisition. Ventyx raised approximately $354.6 million cumulatively across a $51M Series B (September 2021, Surveyor Capital), a $176.6M private placement (September 2022, Redmile Group), a $100M private placement (March 2024), and a $27M strategic investment from Sanofi (September 2024, with a right of first negotiation on VTX3232). The company was acquired by Eli Lilly in early 2026 for approximately $1.2 billion ($14.00 per share, all cash), completing in Q1 2026 and resulting in delisting from Nasdaq.

Name

Ventyx Biosciences

Legal name

Ventyx Biosciences, Inc.

Website

https://ventyxbio.com

Company type

Private

Founded year

2021

Operating status

Acquired

Headcount range

101–250 employees

Short description

Ventyx Biosciences was a clinical-stage biopharmaceutical company developing oral NLRP3 inflammasome inhibitors for autoimmune and inflammatory diseases including Parkinson's, cardiovascular risk, IBD, and recurrent pericarditis; founded 2018 in San Diego, it was acquired by Eli Lilly in 2026 for $1.2B.

Ownership category

akta.pro rank

Product category

Clinical-stage Biopharmaceuticals

NAICS

Medicinal and Botanical Manufacturing (325411), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industries

Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI), Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)

Keywords

• NLRP3 inhibitors
• Inflammatory disease therapeutics
• Oral small molecules
• Biopharmaceutical drug development
• Autoimmune disorder treatments

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Drug Development and Potential Commercialization: Pre-revenue clinical-stage biopharmaceutical company developing pipeline of oral NLRP3 inhibitors for inflammatory diseases. No commercialized products. Revenue potential dependent on successful clinical development and regulatory approval, or on partnership/acquisition transactions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Ventyx Biosciences is a clinical-stage biopharmaceutical company developing a pipeline of oral small molecule NLRP3 inflammasome inhibitors for inflammatory-mediated diseases. Its assets target cardiometabolic disorders, neuroinflammatory/neurodegenerative conditions such as Parkinson's disease, recurrent pericarditis, and inflammatory bowel disease. The company had no commercialized products and was acquired by Eli Lilly in early 2026.

Product overview

Ventyx Biosciences is a clinical-stage biopharmaceutical company developing oral small molecule therapeutics targeting the NLRP3 inflammasome for inflammatory-mediated diseases. The company's pipeline centers on NLRP3 inhibitors including VTX3232 (CNS-penetrant for neuroinflammatory and neurodegenerative conditions), VTX2735 (for recurrent pericarditis), VTX958 and tamuzimod (for inflammatory bowel disease), and VEN-201 (for spinal cord injury). The company was acquired by Eli Lilly in early 2026 for approximately $1.2 billion.

Differentiator

Problem solved

Functional benefit

Brands

• VTX3232: CNS-penetrant NLRP3 inhibitor for neuroinflammatory and neurodegenerative conditions such as Parkinson's and Alzheimer's disease
• VTX2735
• Tamuzimod
• VTX958

Products and services

• VTX3232

Quantifiable outcome

• VTX3232 reduced hsCRP (cardiovascular risk biomarker) by nearly 80% within the first week of Phase 2 study in 175 patients with obesity and cardiovascular risk factors.
• +3 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Eli Lilly and CompanycoreStrategic or Co-development Partner · 7 January 2026Eli Lilly agreed to acquire Ventyx Biosciences for approximately $1.2 billion ($14.00 per share in all-cash transaction), expected to close in H1 2026. Deal strengthens Eli Lilly's oral inflammatory drug pipeline with NLRP3 inhibitors targeting cardiometabolic, CNS, and IBD indications. Ventyx shareholders approved the merger on March 3, 2026. Transaction completed and Ventyx delisted from Nasdaq.
• SanoficoreStrategic or Co-development Partner · 23 September 2024Sanofi made a $27 million strategic investment in Ventyx Biosciences, purchasing Series A non-voting preferred stock. The investment grants Sanofi an exclusive right of first negotiation for certain VTX3232 program rights - a CNS-penetrant NLRP3 inhibitor under development for neuroinflammatory conditions. Transaction closed September 23, 2024. Sanofi subsequently engaged in ongoing negotiations regarding VTX3232 rights following positive Phase 2 data in October 2025.

Scale indicators4 records

Recent moves7 records

Expansion highlights4 records

Broad incumbents

• Sanofi: Sanofi took a $27M strategic stake in Ventyx and held right of first negotiation for VTX3232, with substantial inflammation and rare disease franchises (Dupixent). It is a relevant broad incumbent peer and prior partnership counterparty.
• AbbVie: AbbVie operates a broad immunology franchise (Skyrizi, Rinvoq) addressing inflammatory bowel disease and other autoimmune conditions where Ventyx's IL-17 and NLRP3 programs compete. It is a broad incumbent setting commercial and pricing benchmarks.
• Pfizer: Pfizer's etrasimod and broader inflammation pipeline targets IBD and inflammatory diseases overlapping with Ventyx's tamuzimod/VTX958 program. It is a broad incumbent competitor in autoimmune indications.
• Eli Lilly: Eli Lilly acquired Ventyx for $1.2B in 2026 and operates a large cardiometabolic, immunology, and neurology franchise (including GLP-1s) that will develop the Ventyx NLRP3 assets. As the new parent, it defines the development path for the acquired pipeline.
• Roche / Genentech: Roche operates a major immunology and neuroscience franchise (Actemra, Ocrevus) with active inflammasome and neuroinflammation research. It represents broad incumbent competition for Ventyx's CNS and inflammatory assets.
• Bristol Myers Squibb: BMS markets Zeposia (S1P modulator) and has a broad autoimmune/inflammation portfolio overlapping with Ventyx's IBD and inflammatory disease focus. It represents incumbent competitive pressure in the same end indications.

Direct peers

• Novartis (Inflazome/Ildong): Novartis acquired Inflazome's NLRP3 inhibitor portfolio (IZD334 and related programs) targeting inflammatory diseases. It is a direct competitor to Ventyx in the NLRP3 space with substantially greater resources.
• Olatec Therapeutics: Olatec is developing dapansutrile, an oral NLRP3 inhibitor being studied in inflammatory and cardiometabolic indications including cardiovascular disease and gout. It is the most direct NLRP3-mechanism peer to Ventyx's pipeline.
• Inflazome (acquired): Inflazome was a clinical-stage NLRP3-focused biotech acquired by Novartis in 2020; its portfolio (IZD334, IZD174) represents the closest mechanistic peer to Ventyx's pipeline and validates pharma appetite for NLRP3 assets.

Emerging players

• Zydus Lifesciences: Zydus has advanced NLRP3 and inflammasome-related research programs in cardiometabolic and inflammatory indications. As an emerging player with partial mechanistic overlap, it represents an additional competitive threat to Ventyx's positioning.

Market position

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/ventyx-biosciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds5 records

Investors26 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ventyx Biosciences